Amgen begins late-stage trials for obesity therapy
by Contributor since / Followers
4 weeks ago
JHVEPhoto
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and
